Liquidia (LQDA) vs NewAmsterdam Pharma N.V. (NAMS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Liquidia (LQDA) has outperformed NewAmsterdam Pharma N.V. (NAMS) over the past year, gaining 16.4% versus a loss of 35.3%. Over five years, LQDA leads with a +775.6% price change compared with +117.2% for NAMS. NewAmsterdam Pharma N.V. is the larger company by market cap ($2.52 billion vs $2.50 billion), about 1.0 times the size, while Liquidia is growing revenue faster (+1031.2% vs -50.6%).
Liquidia converts more of its revenue into profit, with a net margin of -43.5% versus -905.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LQDA | NAMS |
|---|---|---|
| Share price | $27.93 | $21.57 |
| Market cap | $2.50B | $2.52B |
| 1-day change | -0.32% | +1.43% |
| YTD return | -18.76% | -39.40% |
| 1-year return | +16.36% | -35.30% |
| 5-year return | +775.63% | +117.16% |
| P/E ratio (TTM) | 20.09 | — |
| Forward P/E | 11.62 | — |
| EPS (TTM) | $1.39 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $158.32M | $22.50M |
| Revenue growth (YoY) | +1031.18% | -50.61% |
| Net income (latest FY) | $-68.92M | $-203.82M |
| Operating margin | -32.45% | -1002.90% |
| Net margin | -43.53% | -905.74% |
| 52-week high | $93.61 | $42.21 |
| 52-week low | $21.94 | $20.91 |
| Distance from 52-week high | -70.16% | -48.90% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +77.84% | +130.23% |
| Average volume | 2.47M | 1.36M |
| Shares outstanding | 89.51M | 116.90M |
| Employees | 216 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LQDA has outperformed NAMS by 51.7 percentage points over the past year.
- Liquidia is more profitable, keeping -43.5 cents of every revenue dollar as net income versus -905.7 cents for NewAmsterdam Pharma N.V..
- Liquidia grew revenue faster in its latest fiscal year (+1031.18% vs -50.61%).
About Liquidia
LQDA stock →Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Health Care · Biotechnology: Pharmaceutical Preparations · 216 employees
About NewAmsterdam Pharma N.V.
NAMS stock →NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
LQDA vs NAMS FAQ
Which is bigger, Liquidia or NewAmsterdam Pharma N.V.?
NewAmsterdam Pharma N.V. (NAMS) is larger, with a market capitalization of $2.52B compared with $2.50B for Liquidia (LQDA).
Which stock has performed better over the past year, LQDA or NAMS?
LQDA returned +16.36% over the past 12 months, compared with -35.30% for NAMS (price return, excluding dividends). Past performance does not predict future results.
Are Liquidia and NewAmsterdam Pharma N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.